SCHEMBL1133034

SCHEMBL1133034

CCN(C[C@H](CO)NC)C(C)(C)c1ccccc1OC

nearest known ligand 0.34

Predicted protein targets (top 19)

geneUniProtsupporting neighboursconfidence
LMNA P02545 2/20 0.34
MEN1 O00255 2/20 0.34
KMT2A Q03164 2/20 0.34
AGTR1 P30556 1/20 0.34
CYP1A2 P05177 1/20 0.34
ALDH1A1 P00352 3/20 0.33
ATM Q13315 1/20 0.33
GAA P10253 3/20 0.32
CYP2D6 P10635 1/20 0.32
CYP2C19 P33261 1/20 0.32
CASR P41180 1/20 0.31
MAPT P10636 1/20 0.31
MAPK1 P28482 1/20 0.31
HTT P42858 1/20 0.31
MC4R P32245 1/20 0.30
SLC6A2 P23975 1/20 0.30
SLC6A4 P31645 1/20 0.30
ROCK2 O75116 1/20 0.30
ROCK1 Q13464 1/20 0.30

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL1133037 1.00 LMNA (0.34) LMNAMEN1KMT2AAGTR1CYP1A2
SCHEMBL1132332 0.86 ALDH1A1 (0.38) LMNAMEN1KMT2AAGTR1CYP1A2
SCHEMBL12608414 0.81 LMNA (0.35) LMNAMEN1KMT2AAGTR1CYP1A2
SCHEMBL12565863 0.79 LMNA (0.33) LMNAMEN1KMT2AAGTR1CYP1A2
SCHEMBL12565814 0.78 ADRA2B (0.38) LMNAMEN1KMT2AALDH1A1ATM
SCHEMBL1132831 0.78 KMT2A (0.35) LMNAMEN1KMT2AALDH1A1MC4R
SCHEMBL12566084 0.77 ALDH1A1 (0.37) LMNAMEN1KMT2AAGTR1CYP1A2
SCHEMBL12608597 0.76 ALDH1A1 (0.36) LMNAMEN1KMT2AAGTR1CYP1A2
SCHEMBL1132904 0.75 ALDH1A1 (0.38) LMNAMEN1KMT2ACYP1A2ALDH1A1
SCHEMBL1132372 0.74 AGTR1 (0.37) LMNAMEN1KMT2AAGTR1CYP1A2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8299035-B2 10a-azalide compound having 4-membered ring structure TAISHO PHARMACEUTUCAL CO., LTD. (JP) 2012-10-30 US disclosed
US-20110152239-A1 10A-AZALIDE COMPOUND HAVING 4-MEMBERED RING STRUCTURE TAISHO PHARMACEUTICAL CO., LTD. (JP) 2011-06-23 US disclosed
EP-2287173-A1 10A-AZALIDE COMPOUND HAVING 4-MEMBERED RING STRUCTURE Taisho Pharmaceutical Co., Ltd. (JP) 2011-02-23 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20110152239-A1 10A-AZALIDE COMPOUND HAVING 4-MEMBERED RING STRUCTURE ELOVL3, ELOVL5, SCD5 LMNA 1555/4885MEN1 3582/4885KMT2A 695/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.